triple agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-11-24 and is reviewed periodically as new material appears.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Studied for metabolic indications |
| Receptor activity | GIP, GLP-1, and glucagon | Single molecule, three targets |
| Development status | Investigational | Not an approved therapy |
| Common synonym | LY3437943 | Development designation |
| Administration route | Subcutaneous injection | As used in clinical studies |
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
=== Engine === Chainsaw engines are traditionally either a two-stroke single-cylinder gasoline (petrol) internal combustion engine (usually with a cylinder volume of 30 to 120 cc) or an electric motor driven by a battery or electric power cord. In a petrol chainsaw, fuel is generally supplied to the engine by a carburetor at the intake. Two-stroke engines have been preferred for chainsaws due to their higher power-to-weight ratio and simplicity. Hydraulic power may be used for chainsaws for underwater use. To allow use in any orientation, modern gasoline chainsaws use a diaphragm carburetor, which draws fuel from the tank using the alternating pressure differential within the crankcase. Early engines used carburetors with gravity fed float chambers, which caused the engine to stall when tilted. The carburetor may need to be adjusted to maintain an appropriate idle speed and air-fuel ratio, such as when moving to a higher/lower altitude or as the air filter clogs. Carburetors are adjusted either by the operator or, in some saws, automatically by an electronic control unit. To prevent vibration induced injury and reduce user fatigue, saws generally have an anti-vibration system to physically decouple the handles from the engine and bar. This is achieved by constructing the saw in two pieces, connected by springs or rubber in the same way an automobile suspension isolates the chassis from the wheels and road. In cold weather, carburetor icing can occur, so many saws have a vent between the cylinders and carburetor which may be opened to allow hot air to pass.
In February 2025, Trump signed an executive order that directed the Committee on Foreign Investment in the United States (CFIUS) to restrict Chinese investment in strategic economic areas. Trump blamed China for the opioid crisis in the United States. He said the tariffs are intended to pressure China to do more to stop the flow of fentanyl into the US. Opioids, predominantly fentanyl, have killed over 500,000 Americans since 2012. In September 2025, Trump asked the EU to impose 100% tariffs on China to punish it for buying Russian oil and de facto financing Russia's invasion of Ukraine.
==== Overview ==== In July 2012, GSK pleaded guilty in the United States to criminal charges, and agreed to pay US$3 billion, in what was the largest settlement until then between the Justice Department and a drug company. The US$3 billion included a criminal fine of US$956,814,400 and forfeiture of US$43,185,600. The remaining US$2 billion covered a civil settlement with the government under the False Claims Act. The investigation was launched largely on the basis of information from four whistleblowers who filed qui tam (whistleblower) lawsuits against the company under the False Claims Act. The charges stemmed from GSK's promotion of the anti-depressants Paxil (paroxetine) and Wellbutrin (bupropion) for unapproved uses from 1998 to 2003, specifically as suitable for patients under the age of 18, and from its failure to report safety data about Avandia (rosiglitazone), both in violation of the Federal Food, Drug, and Cosmetic Act. Other drugs promoted for unapproved uses were two inhalers, Advair (fluticasone/salmeterol) and Flovent (fluticasone propionate), as well as Zofran (ondansetron), Imitrex (sumatriptan), Lotronex (alosetron) and Valtrex (valaciclovir). The settlement also covered reporting false best prices and underpaying rebates owed under the Medicaid Drug Rebate Program, and kickbacks to physicians to prescribe GSK's drugs. There were all-expenses-paid spa treatments and hunting trips for doctors and their spouses, speakers' fees at conferences, and payment for articles ghostwritten by the company and placed by physicians in medical journals.
Sources: en.wikipedia.org
A styptic (also spelled stiptic) is a specific type of antihemorrhagic agent that works by contracting tissue to seal injured blood vessels. Styptic pencils contain astringents. A common delivery system for this is a styptic or hemostatic pencil (not to be confused with a caustic pencil). This is a short stick of medication. Anhydrous aluminium sulfate is the main ingredient and acts as a vasoconstrictor in order to disable blood flow. The stick is applied directly to the bleeding site. The high ionic strength promotes flocculation of the blood, and the astringent chemical causes local vasoconstriction. Before safety razors were invented, a styptic pencil was a standard part of a shaving kit and was used to seal shaving cuts. Some people continue to use styptic pencils for minor skin wounds from safety or electric razors. Styptic powder is used in the veterinary trade to stop bleeding from nails that are clipped too closely. This powder is generally used on animals, such as cats, dogs, and rabbits, whose vein is found in the center of the nail.
==== Television ==== Grey's Anatomy, a long-running TV series, approached the topic of EDS in its 13th season. In the episode "Falling Slowly", the show's doctors are confronted with confusion when faced with diagnosing a patient. Due to complex and contradicting symptoms presented by the patient, the show's doctors ultimately give the diagnosis of EDS. This episode was based on conversations held by producers who talked with a patient and doctor who have EDS.
For example, the dioxide (FlO2) is expected to be highly unstable to decomposition into its constituent elements (and would not be formed by direct reaction of flerovium with oxygen), and flerovane (FlH4), which should have Fl–H bond lengths of 1.787 Å and would be the heaviest homologue of methane (the lighter compounds include silane, germane and stannane), is predicted to be more thermodynamically unstable than plumbane, spontaneously decomposing to flerovium(II) hydride (FlH2) and H2. The tetrafluoride FlF4 would have bonding mostly due to sd hybridizations rather than sp3 hybridizations, and its decomposition to the difluoride and fluorine gas would be exothermic. The other tetrahalides (for example, FlCl4 is destabilized by about 400 kJ/mol) decompose similarly. The corresponding polyfluoride anion FlF2−6 should be unstable to hydrolysis in aqueous solution, and flerovium(II) polyhalide anions such as FlBr−3 and FlI−3 are predicted to form preferentially in solutions. The sd hybridizations were suggested in early calculations, as flerovium's 7s and 6d electrons share about the same energy, which would allow a volatile hexafluoride to form, but later calculations do not confirm this possibility. In general, spin–orbit contraction of the 7p1/2 orbital should lead to smaller bond lengths and larger bond angles: this has been theoretically confirmed in FlH2. Still, even FlH2 should be relativistically destabilized by 2.6 eV to below Fl+H2; the large spin–orbit effects also break down the usual singlet–triplet divide in the group 14 dihydrides.
Sources: en.wikipedia.org
== Social and cultural implications == Nipple pain during breastfeeding may affect the family life of mothers. On average, mothers and infants need to make 36 visits to healthcare providers for nipple pain in their first year, leading to a huge household expense. Meanwhile, mothers may shorten breastfeeding duration and switch to artificial infant milk in order to prevent suffering from the pain. Besides, the painful experience may affect the relationship between parents and children as mothers may develop depression, tension and mood disturbances during breastfeeding.
The tea served on New Year's Day and at weddings is sometime kelp tea because the pronunciation of kombu is similar to that of the last part of "yorokobu" (喜ぶ, meaning "be happy"). Fuku-cha(福茶, meaning "fortune tea") is sencha green tea with kombu, umeboshi (pickled plum), kuromame (black beans), and sanshō (Japanese pepper) and is drunk on the last day of the year (Ōmisoka), in New Year, and on the day before the beginning of spring (Setsubun) in Kansai region, wishing a long life. In particular, in New Year, oo-buku-cha or dai-buku-cha (大福茶, meaning "very good fortune tea"), which is sencha green tea with kombu and umeboshi, is drunk in Kansai region wishing good health and happiness.
The UK government says that a report published on the GOV.UK website on 27 December that said housing asylum seekers on the Bibby Stockholm barge was discriminatory on the grounds of age and sex was published by mistake. The report is deleted from the website. 30 December Eurostar services to and from London St Pancras are cancelled because of a flood in a tunnel under the River Thames. British Army officer Preet Chandi becomes the fastest woman to complete a trek to the South Pole on skis. Four police officers are injured and eight people arrested following a demonstration in Camberwell, south London, relating to tensions in the local Eritrean community. 31 December American XL bully dogs are added to the list of banned species under the Dangerous Dogs Act 1991 in England and Wales, requiring them to be on a lead and muzzled in public. It is also illegal to breed, sell or abandon the dogs. Eurostar resumes services to and from London St Pancras following the previous day's disruption. Two people killed in an avalanche at the French ski resort of Saint-Gervais-les-Bains on 28 December are named as British mother and son Kate and Archie Vokes.
Sources: en.wikipedia.org
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.
It is characterized in the literature as an investigational agent under clinical study. Approval status depends on jurisdiction, and readers should check current regulatory information rather than assume availability.
The combination is intended to pair appetite-related and glucose-related effects with mechanisms that increase energy expenditure. Whether the combined profile offers advantages over simpler agonists is the subject of ongoing research.
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.